134 related articles for article (PubMed ID: 21817841)
1. [The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD)].
Shiwa T; Kawanami Y; Yokoyama T; Moritani A; Hashimoto M; Gotoh T
Nihon Shokakibyo Gakkai Zasshi; 2011 Aug; 108(8):1383-92. PubMed ID: 21817841
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.
Park H; Shima T; Yamaguchi K; Mitsuyoshi H; Minami M; Yasui K; Itoh Y; Yoshikawa T; Fukui M; Hasegawa G; Nakamura N; Ohta M; Obayashi H; Okanoue T
J Gastroenterol; 2011 Jan; 46(1):101-7. PubMed ID: 20658156
[TBL] [Abstract][Full Text] [Related]
3. Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease.
Hughes EA; Tracey I; Singhal S; Patel J
Med Hypotheses; 2006; 67(6):1463-4. PubMed ID: 16831521
[No Abstract] [Full Text] [Related]
4. [Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease].
Abel T; Fehér J; Dinya E; Gamal Eldin M; Kovács A
Orv Hetil; 2009 May; 150(21):989-93. PubMed ID: 19443308
[TBL] [Abstract][Full Text] [Related]
5. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.
Enjoji M; Machida K; Kohjima M; Kato M; Kotoh K; Matsunaga K; Nakashima M; Nakamuta M
Lipids Health Dis; 2010 Mar; 9():29. PubMed ID: 20222991
[TBL] [Abstract][Full Text] [Related]
6. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?
Enjoji M; Nakamuta M
World J Gastroenterol; 2010 Feb; 16(7):800-3. PubMed ID: 20143458
[TBL] [Abstract][Full Text] [Related]
7. Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.
Yoshida M
Curr Vasc Pharmacol; 2011 Jan; 9(1):121-3. PubMed ID: 21044016
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
[TBL] [Abstract][Full Text] [Related]
9. Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis.
Yoneda M; Fujita K; Imajo K; Mawatari H; Kirikoshi H; Saito S; Nakajima A
J Gastroenterol; 2011 Mar; 46(3):415-6; author reply 417. PubMed ID: 21181211
[No Abstract] [Full Text] [Related]
10. The effect of ezetimibe on NAFLD.
Averna M
Atheroscler Suppl; 2015 Feb; 17():27-34. PubMed ID: 25659874
[TBL] [Abstract][Full Text] [Related]
11. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.
Takeshita Y; Takamura T; Honda M; Kita Y; Zen Y; Kato K; Misu H; Ota T; Nakamura M; Yamada K; Sunagozaka H; Arai K; Yamashita T; Mizukoshi E; Kaneko S
Diabetologia; 2014 May; 57(5):878-90. PubMed ID: 24407920
[TBL] [Abstract][Full Text] [Related]
12. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (2005) 6(1):131-139.
Ahmed MH; Saad RA; Osman MM
Expert Opin Drug Saf; 2006 Jul; 5(4):487-8. PubMed ID: 16774486
[No Abstract] [Full Text] [Related]
14. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ahmed MH; Byrne CD
Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
[TBL] [Abstract][Full Text] [Related]
15. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
[TBL] [Abstract][Full Text] [Related]
17. Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD?
Musso G
Diabetologia; 2014 May; 57(5):850-5. PubMed ID: 24554006
[No Abstract] [Full Text] [Related]
18. Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events.
Ahmed MH; Byrne CD
Diabetes Obes Metab; 2010 Nov; 12(11):958-66. PubMed ID: 20880342
[TBL] [Abstract][Full Text] [Related]
19. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
Nozaki Y; Fujita K; Yoneda M; Wada K; Shinohara Y; Takahashi H; Kirikoshi H; Inamori M; Kubota K; Saito S; Mizoue T; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
J Hepatol; 2009 Sep; 51(3):548-56. PubMed ID: 19596472
[TBL] [Abstract][Full Text] [Related]
20. Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model.
Oishi T; Terai S; Kuwashiro S; Fujisawa K; Matsumoto T; Nishina H; Sakaida I
Biochem Biophys Res Commun; 2012 May; 422(1):22-7. PubMed ID: 22554516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
